Results 101 to 110 of about 227,212 (304)

The use of angiotensin-converting enzyme inhibitors in general medicine

open access: yesSouth African Family Practice, 2012
Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs commonly used in the management of hypertension, congestive heart failure, cerebrovascular disease, stable coronary heart disease and diabetes-associated nephropathy.
M.L.I. Mashitisho
doaj   +1 more source

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki   +11 more
wiley   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

Lung Diseases and Angiotensin-Converting Enzyme

open access: yesEurasian Journal of Medicine, 2019
-
Mecit Süerdem
doaj  

Pharmacotherapy and analysis of gaseous mediators in hypertensive patients

open access: yesRevista da Escola de Enfermagem da USP, 2015
OBJECTIVE To evaluate the effect of using antihypertensive classes of drugs of the calcium channel antagonists and inhibitors of angiotensin-converting enzyme in plasma concentrations of hydrogen sulfide and nitric oxide in patients with hypertension ...
Letícia Palota Eid   +4 more
doaj   +1 more source

Angiotensin-converting enzyme insertion/deletion (I/D) genotype frequencies in cases and controls.

open access: yes, 2016
Angiotensin-converting enzyme insertion/deletion (I/D) genotype frequencies in cases and controls.
Hung Chang (550361)   +13 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

The Effect of Eight-Week Aerobic Training on Serum Angiotensin Converting Enzyme and Lipid Profile in Inactive Overweight Women [PDF]

open access: yesJournal of Advanced Biomedical Sciences, 2019
Background & Objective: At present, the prevalence of hypertension is growing and one of the contributing factors in the occurrence and development of hypertension and atherosclerosis is impaired renin–angiotensin system which in this system endothelium ...
nahid Bijeh   +4 more
doaj  

The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with OSA: a meta-analysis

open access: yes, 2014
Obstructive sleep apnoea (OSA) is an independent risk factor for hypertension. Increased angiotensin-converting enzyme (ACE) activity may be a possible promoting mechanism with different ACE insertion/deletion (I/D) genotypes influencing this activity ...
李佩玲   +1 more
core   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy